457 results on '"Kharas, Michael G"'
Search Results
2. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
3. A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies
4. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
5. SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells
6. Transcriptional control of CBX5 by the RNA-binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia
7. High Fructose Drives the Serine Synthesis Pathway in Acute Myeloid Leukemic Cells
8. Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target
9. Design and Development of IKZF2 and CK1α Dual Degraders
10. SON is an essential m6A target for hematopoietic stem cell fate
11. Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase
12. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells
13. ChromaFold predicts the 3D contact map from single-cell chromatin accessibility
14. Supplementary Tables 1-6 from Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
15. Data from Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
16. Supplementary Figures 1-8 from Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
17. Stem Cells, Cancer, and MUSASHI in Blood and Guts
18. RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction
19. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
20. Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
21. Table S5 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
22. Data from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
23. Supplementary Figures from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
24. Supplementary Methods from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
25. Supplementary Table Captions from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
26. Supplementary Materials and Methods from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
27. Data from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
28. Supplementary Figure 3 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
29. Supplementary Figure 1 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
30. Supplementary Figure 4 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
31. Supplementary Table 1 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
32. Supplementary Figure 2 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
33. Supp tables 1-5 from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
34. Supp Methods from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
35. Supp Figs 1-5 from Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
36. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
37. BTG1 mutation yields supercompetitive B cells primed for malignant transformation
38. Fructose Treatment Targets Myeloid Leukemogenesis in IDH2 Mutants By Exhausting Alpha-Ketoglutarate Pools
39. Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
40. Dual IKZF2 and CK1α Degrader Targets Acute Myeloid Leukemia Cells
41. Abstract A24: BTG1 mutations confer a fitness advantage and promote aggressive B cell lymphoma development by lowering the threshold for MYC induction
42. In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling
43. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program
44. Sjögren's Syndrome-Like Disease in Mice with T Cells Lacking Class 1A Phosphoinositide-3-Kinase
45. Decoding m6A, one reader at a time
46. TP53 Mutations and RNA Binding Protein Musashi 2 Drive Resistance to PRMT5-Targeted Therapy in B-Cell Lymphoma
47. BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells
48. RNA Binding Protein Syncrip Is Required for the Low-Output HSC By Sustaining Proteome Quality
49. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
50. Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.